Phasing of Project Execution

The execution of the project initially will be responsibility of HD and University through project execution/management committee till functional BoDs ensues. Other committees for execution will include a Technical Committee, a recruitment committee and a procurement committee with prescribed role and responsibilities. The project execution will encompass:


Phase I:


Initial phase during which much of project planning and functional structure will be developed. It will comprise of selection of private sector partner, development of legal contract between the partners, establishment of BoD, development of operational strategies and bylaws.


The phase will include initial experimentation period for which animals will be purchased for various technique learning, development of SOPs, training of staff and definitely for transfer of technology. Initially 15 horses, 10 sheep and a reasonable number of snakes will be purchased for the purpose. Learning Venom purification and fractionation together with horses inoculation and learning ELISA methods of Anti Bodies titer assessment will be the core elements of such initial experimentation phase. The visiting international experts will teach/ demonstrate practical learning of various techniques and lab procedures to the project staff on such animals.

A “Public-Private Partnership” concern to be set up through Government of Sindh Law Department guidelines as “ASV/ARV Project” possessing full autonomy under the governing body with representation from the Government of Sindh, University and Private Partner and managed by a BoDs through Project Director.


This phase will continue till the completion of civil works, acquisition and installation of machinery, laboratory for QA/QC,  recruitment and training of staff, land acquisition and development of animal farm, purchase of snakes, venom extraction and freeze drying, advance training of technical personnel, development of processes, protocols, SOPs, licensing, registration, preliminary pre-production activities and trial production. The first phase will encompass 60 months and it is firmly anticipated that by the end of first phase the proposed lab will be able to produce adequate quantity of ASV to meet 90% or more of provincial needs.

Phase II.

Implementation of the project for manufacturing actual production of ASV for marketing and human use. The phase will incorporate expansion of lab to incorporate manufacturing of ARV and other similar anti-sera or vaccines. For which a separate PC-1 will be submitted in the light of earlier experience.